-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 2, 2021, Luoxin Pharmaceutical Group Co.
Exclusive formulation fills the gap in the market
Luoxin Pharmaceuticals actively responds to the national call and is guided by the clinical needs of pediatrics.
Accompanying the occurrence of influenza and other diseases, the symptoms of coughing and sputum in children are on average 2 times a year, but there is no clinically dedicated medicine for expectorating children between 2-6 years old
As the first and only child-specific expectorant spray in China, the approval of ambroxol hydrochloride spray is expected to solve the problem that existing dosage forms cannot meet clinical needs, and enable high-quality innovative drugs to better serve The field of medicine for children in China
Classic expectorant products
Occupies 3/4 of the total expectorant market
As a classic drug, ambroxol hydrochloride is widely used not only in respiratory medicine, but also in pediatrics.
According to data from IQVIA and Meinenet, the global sales of ambroxol hydrochloride in 2020 will be 587 million U.
Focus on the field of respiratory diseases
Innovate for clinical needs
The company said that ambroxol hydrochloride spray is another major product in the field of respiratory diseases, which has opened up the children's drug market, which is conducive to further enhancing market competitiveness and expanding market share
Liu Zhenteng, Chairman and CEO of Luoxin Pharmaceutical, said: “We are very pleased to see the approval of ambroxol hydrochloride spray.
